ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

MXCT MaxCyte Inc

3.77
-0.06 (-1.57%)
04 5월(5) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
MaxCyte Inc MXCT 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
-0.06 -1.57% 3.77 07:30:10
개장가 저가 고가 종가 전일 종가
3.95 3.74 3.95 3.77 3.83
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
10/04/202421:05GLOBEMaxCyte to Report First Quarter 2024 Financial Results on..
02/04/202421:05GLOBEMaxCyte Signs Strategic Platform License with Be Biopharma..
13/03/202405:05GLOBEMaxCyte Reports Fourth Quarter and Full Year 2023 Financial..
06/03/202406:15EDGAR2Form 8-K - Current report
05/03/202407:39EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/03/202406:05GLOBEMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023..
27/02/202406:22EDGAR2Form 144 - Report of proposed sale of securities
15/02/202406:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
15/02/202402:25EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09/02/202422:05GLOBEMaxCyte to Report Fourth Quarter and Full Year 2023..
02/02/202406:25EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
31/01/202406:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/01/202422:05GLOBEMaxCyte and Wugen Sign Strategic Platform License to..
27/01/202406:45EDGAR2Form 8-K - Current report
27/01/202401:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
23/01/202422:05GLOBEMaxCyte Signs Strategic Platform License with Imugene to..
09/01/202406:15EDGAR2Form 8-K - Current report
09/01/202406:05GLOBEMaxCyte Announces Preliminary Unaudited Fourth Quarter and..
05/01/202406:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/01/202422:05GLOBEMaxCyte and Lion TCR form Partnership to Support Global..
02/01/202416:00GLOBEMaxCyte Confirms Appointment of Maher Masoud as President,..
29/12/202306:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202306:30EDGAR2Form 8-K - Current report
12/12/202306:05GLOBEMaxCyte Announces CEO Transition and Updates Revenue..
07/12/202306:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/12/202307:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/11/202306:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/11/202306:32EDGAR2Form 144 - Report of proposed sale of securities
18/11/202306:05EDGAR2Form SC 13G - Statement of acquisition of beneficial..
17/11/202306:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/11/202322:05GLOBEMaxCyte Joins the Alliance for mRNA Medicines (AMM) as a..
09/11/202307:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202306:12EDGAR2Form 8-K - Current report
09/11/202306:05GLOBEMaxCyte Reports Third Quarter 2023 Financial Results and..
07/11/202306:05GLOBEMaxCyte to Participate in Two Upcoming Investor Conferences
05/10/202305:14EDGAR2Form 8-K - Current report
05/10/202305:05GLOBEMaxCyte Announces Preliminary Third Quarter 2023 Revenue and..
06/09/202321:05GLOBEMaxCyte Appoints Ali Soleymannezhad as Executive Vice..
05/09/202321:05GLOBEMaxCyte to Participate in Baird Global Healthcare Conference
31/08/202306:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/08/202305:55EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/08/202305:16EDGAR2Form 8-K - Current report
10/08/202305:05GLOBEMaxCyte Reports Second Quarter and Half-Year 2023 Financial..
01/08/202321:05GLOBEMaxCyte Signs Strategic Platform License with Prime Medicine..
29/07/202305:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/07/202321:05GLOBEMaxCyte to Report Second Quarter 2023 Financial Results on..
13/07/202307:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/07/202305:51EDGAR2Form 144 - Report of proposed sale of securities
10/07/202321:05GLOBEMaxCyte and Vittoria Biotherapeutics Sign Strategic Platform..
06/07/202321:05GLOBEMaxCyte Signs Strategic Platform License with Lyell..

최근 히스토리

Delayed Upgrade Clock